Abstract
Polo-Like Kinase (PLK1) has been identified as a potential target in cancer gene therapy via chemical or genetic inhibitory approaches. The biomedical applications of chemically functionalized carbon nanotubes (f-CNTs) in cancer therapy have been studied due to their ability to efficiently deliver siRNA intracellularly. In this study, we established the capacity of cationic MWNT-NH3(+) to deliver the apoptotic siRNA against PLK1 (siPLK1) in Calu6 tumor xenografts by direct intratumoral injections. A direct comparison with cationic liposomes was made. This study validates the PLK1 gene as a potential target in cancer gene therapy including lung cancer, as demonstrated by the therapeutic efficacy of siPLK1:MWNT-NH3(+) complexes and their ability to significantly improve animal survival. Biological analysis of the siPLK1:MWNT-NH3(+) treated tumors by qRT-PCR and Western blot, in addition to TUNEL staining confirmed the biological functionality of the siRNA intratumorally, suggesting that tumor eradication was due to PLK1 knockdown. Furthermore, by using a fluorescently labeled, noncoding siRNA sequence complexed with MWNT-NH3(+), we established for the first time that the improved therapeutic efficacy observed in f-CNT-based siRNA delivery is directly proportional to the enhanced siRNA retention in the solid tumor and subsequent uptake by tumor cells after local administration in vivo.
Original language | English |
---|---|
Pages (from-to) | 1370-1379 |
Journal | Bioconjugate Chemistry |
Volume | 26 |
Issue number | 7 |
DOIs | |
Publication status | Published - 15 Jul 2015 |
Externally published | Yes |
Keywords
- Animals
- Apoptosis
- Cations
- Cell Cycle Proteins
- Cell Line, Tumor
- Female
- Genetic Vectors
- Humans
- Lung
- Lung Neoplasms
- Mice, Nude
- Nanotubes, Carbon
- Protein-Serine-Threonine Kinases
- Proto-Oncogene Proteins
- RNA Interference
- RNA, Small Interfering
- RNAi Therapeutics
- Journal Article
- Research Support, Non-U.S. Gov't